SC 100

Drug Profile

SC 100

Alternative Names: Anti-epidermal growth factor receptor antibody SC 100; SC100

Latest Information Update: 07 Apr 2008

Price : $50

At a glance

  • Originator Scancell
  • Developer ISU Chemical; Scancell
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 12 Feb 2002 Preclinical development for Cancer in South Korea (Unknown route)
  • 12 Feb 2002 Preclinical development for Cancer in Asia (Unknown route)
  • 12 Feb 2002 Preclinical development for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top